Phase 3 clinical testing typically includes how many volunteers?

Phase 3 clinical testing is a critical stage in drug development where the drug's efficacy and safety are further assessed. During this phase, a larger population of volunteers is involved compared to earlier phases. The primary purpose is to confirm the effectiveness of the drug, monitor side effects, and compare it to commonly used treatments.

Typically, Phase 3 trials enroll a substantially large number of participants, generally ranging from 1,000 to 5,000 individuals. This higher enrollment ensures the data gathered is more robust and allows for the detection of less common adverse reactions, providing a comprehensive understanding of the medication's impact across different demographics.

In contrast, earlier phases of clinical trials involve much smaller sample sizes due to their primary focus on safety, dosage, and pharmacokinetics. The significant difference in participant numbers across phases is crucial for achieving reliable results that regulatory bodies can use to make informed decisions regarding a drug's approval for public use. The option indicating 1000-5000 participants aligns perfectly with the standard practices of Phase 3 trials, which is why it is the correct choice.